SOURCE: Cypress Bioscience Inc.

Cypress Bioscience Inc.

September 22, 2010 06:30 ET

Cypress Bioscience, Inc. to Present at UBS Global Life Sciences Conference

SAN DIEGO, CA--(Marketwire - September 22, 2010) -  Cypress Bioscience, Inc. (NASDAQ: CYPB) today announced that Jay D. Kranzler, MD, PhD, its Chairman of the Board and Chief Executive Officer, will present at the UBS Global Life Sciences Conference today, September 22, 2010. 

The UBS conference is being held at the Grand Hyatt New York Hotel in New York, NY. Dr. Kranzler is scheduled to present on Wednesday, September 22nd at 11:00 am Eastern Time. The audio broadcast of this presentation can be accessed at http://cc.talkpoint.com/ubsx001/092110a_lv/?entity=103_228VY3Y.

A replay of the presentation will be available at the same web address as well as on Cypress' website, http://www.cypressbio.com/events.php.

About Cypress Bioscience
Cypress Bioscience is a pharmaceutical company dedicated to the development of innovative drugs targeting large unmet medical needs for patients suffering from a variety of disorders of the central nervous system. Since 1999, Cypress has received multiple FDA approvals, including for Prosorba™, a medical device for rheumatoid arthritis, and Savella® (milnacipran HCl), for fibromyalgia. The Company focuses on generating stockholder value by reaching clinical development milestones as quickly and efficiently as possible. Cypress' currently marketed products include Savella and the Avise PG(SM) and Avise MCV(SM) therapeutic monitoring, diagnostic and prognostic testing services for rheumatoid arthritis. Development-stage assets include CYP-1020 for cognitive impairment in schizophrenia, Staccato® nicotine for smoking cessation, intranasal carbetocin for autism, and AVISE-SLE(SM), a lupus diagnostic testing service. More information on Cypress and its products and development assets is available at http://www.cypressbio.com/.

For more information about Cypress, please visit the Company's website at www.cypressbio.com.

Contact Information

  • For additional information please contact

    Mary Gieson
    Investor Relations Manager
    (858) 452-2323
    Email Contact